MarketPulse
O

$ONCO

2 articles found
1 positive
0 negative
1 neutral
BenzingaBenzinga··Mohd Haider

Onconetix Surges 23% on Proclarix Cancer Test Validation, But Stock Down 99% Annually

Biotech firm $ONCO jumped 23.65% after-hours on clinical progress for prostate cancer blood test, despite 99% annual decline.
LHONCObiotechafter-hours trading
BenzingaBenzinga··Lekha Gupta

Onconetix Surges 71% on Realbotix AI Robot Acquisition, Reverse Split

Onconetix shares surge 71.74% premarket after acquiring Realbotix, an AI robotics specialist, but stock remains down 92.97% year-over-year.
ONCOacquisitionreverse stock split